
==== Front
Respir Res
Respir Res
Respiratory Research
1465-9921
1465-993X
BioMed Central London

39252048
2963
10.1186/s12931-024-02963-3
Research
Risk of incident chronic obstructive pulmonary disease during longitudinal follow-up in patients with nontuberculous mycobacterial pulmonary disease
Kim Bo-Guen 12
Shin Sun Hye 3
Lee Sun-Kyung 14
Kim Sang-Heon 1
Lee Hyun namuhanayeyo@hanyang.ac.kr

1
1 https://ror.org/046865y68 grid.49606.3d 0000 0001 1364 9317 Division of Pulmonary Medicine and Allergy, Department of Internal Medicine, Hanyang University College of Medicine, 222-1, Wangsimni-ro, Seongdong-gu, Seoul, 04763 Republic of Korea
2 grid.264381.a 0000 0001 2181 989X Division of Pulmonary Medicine, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
3 grid.264381.a 0000 0001 2181 989X Division of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
4 https://ror.org/046865y68 grid.49606.3d 0000 0001 1364 9317 Department of Mathematics, College of Natural Sciences, Hanyang University, Seoul, Republic of Korea
9 9 2024
9 9 2024
2024
25 33327 3 2024
27 8 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by-nc-nd/4.0/ Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
Background

The Global Initiative for Chronic Obstructive Lung Disease 2023 revision proposed that chronic obstructive pulmonary disease (COPD) has various etiologies including infections (COPD-I), such as tuberculosis and human immunodeficiency virus. While nontuberculous mycobacterial pulmonary disease (NTM-PD) and pulmonary tuberculosis share similar clinical manifestations, research on COPD development during longitudinal follow-up in patients with NTM-PD is limited. In this study, we aimed to evaluate the incidence and risk of COPD development in patients with NTM-PD.

Methods

We retrospectively enrolled patients with NTM-PD with normal lung function and 1:4 age-, sex-, body mass index-, and smoking status-matched controls between November 1994 and January 2022. We compared the risks of spirometry-defined COPD between the NTM-PD and control groups (study 1). A nationwide cohort study using the health insurance claims database was conducted to validate the findings (study 2).

Results

In study 1, during a mean follow-up of 3.3 years, COPD occurred in 14.0% (241/1,715) and 4.3% (293/6,860) of individuals in the NTM-PD and matched control cohorts, respectively. The NTM-PD cohort exhibited a higher risk of incident COPD (adjusted hazard ratio [aHR], 2.57; 95% CI, 2.15–3.09) compared to matched controls. In study 2, COPD occurred in 6.2% (24/386) and 2.5% (28/1,133) of individuals with and without NTM-PD, respectively. The NTM-PD cohort had a higher risk of incident COPD (aHR, 2.04; 95% CI, 1.21–3.42) compared to matched controls.

Conclusion

These findings suggest that NTM-PD could be considered a new etiotype of COPD-I and emphasize the importance of monitoring lung function in individuals with NTM-PD.

Supplementary Information

The online version contains supplementary material available at 10.1186/s12931-024-02963-3.

Keywords

Nontuberculous mycobacterial pulmonary disease
Chronic obstructive pulmonary disease
issue-copyright-statement© BioMed Central Ltd., part of Springer Nature 2024
==== Body
pmcBackground

Chronic obstructive pulmonary disease (COPD) is the third leading cause of mortality worldwide, with more than 3 million deaths per year [1, 2]. To reduce its global burden, the recently revised Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2023 have proposed a new taxonomy (etiotype) to emphasize early recognition of various COPD etiologies. Among them, COPD due to infections (COPD-I) includes childhood infections, tuberculosis-associated COPD, and human immunodeficiency virus-associated COPD [3]. However, other studies have suggested that infections other than these diseases are also associated with obstructive lung disease [4, 5]. The GOLD committee has recommended increased attention to these other infections linked to COPD [6, 7].

Nontuberculous mycobacterial pulmonary disease (NTM-PD) is a chronic and progressing infectious respiratory disease caused by various NTM species, with an increasing incidence worldwide [8]. Airflow obstruction or physician-diagnosed COPD is common in patients with NTM-PD [9]. However, since COPD is a common risk factor for NTM-PD, [10] whether NTM-PD precedes COPD or vice versa remains unclear. Although previous studies have suggested that patients with NTM-PD experience a faster decline in forced expiratory volume in 1 s (FEV1) than that of the general population, [11–14] and coexisting NTM-PD is associated with the faster decline in FEV1 in patients with established COPD, [15, 16] only a few studies have explored whether NTM-PD can serve as an infectious etiotype for COPD [4].

Therefore, the present study aimed to investigate the incidence and risk of developing COPD in patients with NTM-PD with normal lung function. To achieve this, we conducted a retrospective single-center cohort involving a large number of patients with NTM-PD and matched controls and compared the incidences of spirometry-defined COPD between them. To validate the main outcomes, we conducted a nationwide population-based cohort study using the health insurance claim database.

Materials and methods

Data source

Two study designs were developed to investigate the incidence and risk of developing COPD. Study 1 aimed to compare the incidence of COPD between patients with NTM-PD and matched controls, who had undergone a comprehensive health screening examination at the Samsung Medical Center (1,960-bed university-affiliated, tertiary referral hospital). Data were extracted from the Clinical Data Warehouse (CDW) Darwin-C at the Samsung Medical Center [17].

Study 2 aimed to validate the findings of study 1 by evaluating the incidence and risk of newly diagnosed and treated COPD among individuals with and without NTM-PD. We used a nationwide representative dataset of approximately 1,000,000 individuals, the Korean National Health Insurance Service National Sample Cohort (NHIS-NSC), which contains information on demographics, healthcare utilization, health screening examinations, disease diagnosis, drug prescription, and death [18]. Supplementary Method details the methodology of study 2.

Study 1 was approved by the Institutional Review Board of the Samsung Medical Center (IRB no.: SMC 2023-08-084). Study 2 was approved by the Institutional Review Board of the Hanyang University Hospital (IRB no.: HYUH 2023-06-007). The requirement for obtaining informed consent was waived because the CDW and NHIS databases had been constructed after anonymization. These studies were conducted in accordance with the principles of the Declaration of Helsinki.

Study population

In study 1, the NTM-PD group initially included 8,184 patients with NTM-PD who had undergone a spirometry test between November 1994 and January 2022. Exclusion criteria were as follows: (1) an abnormal baseline spirometry result, defined as an FEV1/forced vital capacity (FVC) ratio < 0.7 or a predicted percentage value (%pred) of FEV1 < 80 (n = 5,009); (2) no follow-up spirometry test for at least 1 year after the baseline spirometry (n = 274); and (3) a previous diagnosis of COPD (n = 869). Additionally, exclusion criteria from the NTM-PD group included a history of lung resection surgery (n = 61) and missing data on smoking status (n = 256).

The control group initially included 323,862 participants who underwent a health screening examination with a baseline spirometry test during the same period. After applying the same exclusion criteria and excluding those with an established diagnosis of NTM-PD (n = 687), 90,088 participants were enrolled in this study. We performed propensity score-matching at a ratio of 1:4 based on age, sex, body mass index (BMI), and smoking status, resulting in 1,715 patients in the NTM-PD group and 6,860 participants in the matched control groups (Fig. 1). In study 1, both patients with NTM-PD and controls were followed up from the date of the baseline spirometry until COPD diagnosis, death, or December 31, 2022, whichever occurred first.

Fig. 1 Flowchart of the study population. Abbreviations: NTM-PD, nontuberculous mycobacterial pulmonary disease; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; BMI, body mass index

In study 2, patients with NTM-PD who were free from COPD at baseline and within 1 year after enrollment (n = 386) and 1:3 age- and sex-matched controls without NTM-PD or COPD (n = 1,133) were included (Supplementary Method and Supplementary Fig. 1). To minimize the risk of reverse causality, we implemented a 12-month COPD-free washout period; consequently, patients were followed up from 12 months after the enrollment with the endpoint being death, a COPD diagnosis, or December 31, 2019, whichever occurred first.

Exposure

The exposure variable was NTM-PD. In study 1, we defined NTM-PD as the presence of both International Classification of Disease Codes-10th Revision (ICD-10) codes of A31.0, A31.8, or A31.9 and microbiological findings (≥ 2 positive culture results from separately expectorated sputum samples with the same species, or ≥ 1 positive culture result from bronchial washing, bronchoalveolar lavage, or lung biopsy with species identification) [17]. NTM species were identified using a nested multiplex polymerase chain reaction and reverse hybridization assay of the internal transcribed spacer region of rpoB [19]. In study 2, NTM-PD was defined as a case in which the diagnostic code A31.0, A31.8, or A31.9 was assigned for the main- or sub-diagnosis, and specific medical practice codes (e.g., microbial culture or identification codes) were entered together (Supplementary Method).

Study outcome

The primary outcome was newly diagnosed COPD during the follow-up period. In study 1, COPD was defined as a pre-bronchodilator FEV1/FVC ratio < 0.7. When multiple spirometry results were present, the first date of reporting pre-bronchodilator FEV1/FVC ratio < 0.7 was considered the newly diagnosed COPD date. In study 2, COPD was defined as the presence of ICD-10 codes J43–J44, except J43.0, and COPD medication prescribed at least twice within 1 year [20, 21].

Spirometry and annual lung function decline

The baseline spirometry was defined as the first spirometry taken between 6 months before and 6 months after the date of NTM-PD diagnosis for patients with NTM-PD and as the spirometry taken on the same day as the health screening exam for controls.

Spirometry was performed using the Vmax 22 system (SensorMedics, Yorba Linda, CA, USA) according to the American Thoracic Society/European Respiratory Society guidelines [22]. The absolute values of FEV1 and FVC were obtained, and %pred FEV1 and FVC were calculated using the equation obtained by analyzing the representative values of the Korean population [23]. Lung function decline was calculated as follows: [(last FEV1 or FVC) – (FEV1 or FVC at baseline)]/follow-up duration (years) [11, 24]. Rapid FEV1 decline was defined as a loss in FEV1 of > 60 mL/year [25].

Covariates

In study 1, covariate data were extracted from the CDW including age, sex, BMI, smoking status, and comorbidities (pulmonary tuberculosis, diabetes mellitus, hypertension, ischemic heart disease, and cerebrovascular disease), defined using ICD-10 codes [26–30]. Supplementary Method outlines the definitions of the covariates for study 2.

Statistical analysis

Baseline characteristics were expressed as mean ± standard deviation for continuous variables and number (percentage) for categorical variables. We compared the two groups using the χ2 test for categorical variables and t-tests for continuous variables.

In study 1, we performed a 1:4 propensity score-matching between the NTM-PD and control cohorts based on age, sex, BMI, and smoking status. In study 2, we performed a 1:3 matching between the two cohorts based on age and sex. Standardized mean difference (SMD) was used to examine the balance of covariate distributions between the groups, and an SMD > 0.1 was considered to indicate an imbalance [31].

The cumulative incidence of COPD was determined using the Kaplan–Meier curve. Cox proportional-hazards regression analyses were used to estimate the hazard ratios (HRs) and 95% confidence intervals (CIs) for the comparison of incident COPD between the NTM-PD and matched control cohorts, adjusted for age, sex, BMI, smoking status, and comorbidities (tuberculosis, hypertension, diabetes mellitus, ischemic heart disease, and cerebrovascular disease).

In study 2, the Kaplan–Meier curve and multivariable Cox proportional-hazards regression analyses were used to estimate the comparative risks of incident COPD in the NTM-PD and matched control cohorts. Detailed descriptions of statistical analyses are provided in Supplementary Method. Statistical significance was defined as a two-sided p-value < 0.05, and all analyses were conducted using SAS version 9.4 (SAS Institute Inc., Cary, NC, USA) and R software version 4.2.1 (Vienna, Austria).

Results

Baseline characteristics

Table 1 presents the baseline characteristics of the patients from study 1. Patients with NTM-PD were more likely to be older, women, or had a lower BMI than those without NTM-PD. Most (85.0%) of the patients had never smoked, with no significant difference in the smoking status between the two groups. All comorbidities, except cerebrovascular disease, were more common in the NTM-PD group than in the control group (all p < 0.001). Despite matching, variables including age and sex continued to exhibit differences between the two groups (SMD > 0.1). However, the SMDs markedly decreased (Supplementary Fig. 2), and the SMD for the smoking status was < 0.1.

Table 1 Baseline characteristics of propensity score-matched cohorts

	Before matching	After matching*	
Total
(n = 91,803)	Control group
(n = 90,088)	NTM-PD
group
(n = 1,715)	p	Total
(n = 8,575)	Matched control group
(n = 6,860)	NTM-PD group
(n = 1,715)	SMD	
Age, years	47 ± 10	47 ± 9	62 ± 11	< 0.001	60 ± 10	60 ± 10	62 ± 11	0.207	
Male sex, n (%)	52,344 (57.0)	51,609 (57.3)	735 (42.9)	< 0.001	3,295 (38.4)	2,560 (37.3)	735 (42.9)	0.113	
BMI, kg/m2	23.6 ± 3.0	23.6 ± 3.0	21.5 ± 3.0	< 0.001	22.9 ± 2.7	22.0 ± 2.7	21.5 ± 3.0	0.161	
Smoking status, n (%)				0.383				0.099	
 Never-smoker	74,595 (81.3)	73,187 (81.2)	1,408 (82.1)		7,289 (85.0)	5,881 (85.7)	1,408 (82.1)		
 Ever-smoker	17,208 (18.7)	16,901 (18.8)	307 (17.9)		1,286 (15.0)	979 (14.3)	307 (17.9)		
Comorbidity									
 Pulmonary tuberculosis	590 (0.6)	515 (0.6)	75 (4.4)	< 0.001	122 (1.4)	47 (0.7)	75 (4.4)	0.237	
 Diabetes mellitus	601 (0.7)	502 (0.6)	99 (5.8)	< 0.001	148 (1.7)	49 (0.7)	99 (5.8)	0.288	
 Hypertension	4,182 (4.6)	4,024 (4.5)	158 (9.2)	< 0.001	698 (7.1)	540 (7.9)	158 (9.2)	0.048	
 Ischemic heart disease	530 (0.6)	501 (0.6)	29 (1.7)	< 0.001	75 (0.8)	46 (0.7)	29 (1.7)	0.095	
 Cerebrovascular disease	564 (0.6)	563 (0.6)	1 (0.1)	< 0.001	57 (0.6)	56 (0.8)	1 (0.1)	0.115	
Data are expressed as mean ± standard deviation or number (%)

*Matched with age, sex, BMI, and smoking status

Abbreviations: NTM-PD, nontuberculous mycobacterial pulmonary disease; SMD, standardized mean difference; BMI, body mass index

Lung function decline

At baseline, FEV1, and FEV1/FVC ratio were significantly lower in patients with NTM-PD than in those without NTM-PD (NTM-PD vs. matched control; FEV1, 2.6 vs. 2.7 L, p = 0.017; FEV1/FVC, 0.79 vs. 0.81, p < 0.001), although all patients had normal range of spirometry results. During a mean spirometry follow-up of 3.3 years, the annual decline in FEV1 was greater in patients with NTM-PD than in those without NTM-PD (NTM-PD vs. matched control, − 77.6 vs. −47.3 mL, p < 0.001). Patients with NTM-PD exhibited a higher proportion of rapid FEV1 decline than that of matched controls (45.3% vs. 37.9%, p < 0.001; Table 2).

Table 2 Result of pulmonary function test in the study population

Variables	Total
(n = 91,803)	Control group
(n = 90,088)	NTM-PD group
(n = 1,715)	p	Matched control group
(n = 6,860)	NTM-PD group
(n = 1,715)	p	
Interval between baseline and follow-up spirometry tests, years	3.3 ± 3.0	3.3 ± 3.0	3.3 ± 2.6	0.394	3.2 ± 2.7	3.3 ± 2.6	0.053	
Baseline spirometry								
 FVC, L	3.8 ± 0.8	3.8 ± 0.8	3.3 ± 0.8	< 0.001	3.2 ± 0.7	3.3 ± 0.8	0.011	
 FVC, % predicted	94.9 ± 10.9	95.0 ± 10.8	92.7 ± 12.2	< 0.001	95.5 ± 12.2	92.7 ± 12.2	< 0.001	
 FEV1, L	3.2 ± 0.7	3.2 ± 0.7	2.6 ± 0.6	< 0.001	2.7 ± 0.6	2.6 ± 0.6	0.017	
 FEV1, % predicted	102.3 ± 13.5	102.4 ± 13.4	97.5 ± 12.9	< 0.001	105.4 ± 15.0	97.5 ± 12.9	< 0.001	
 FEV1/FVC (%)	82.9 ± 5.5	83.0 ± 5.4	79.0 ± 6.3	< 0.001	81.4 ± 5.8	79.0 ± 6.3	< 0.001	
Follow-up spirometry								
 FVC, L	3.7 ± 0.8	3.8 ± 0.8	3.1 ± 0.8	< 0.001	3.2 ± 0.7	3.1 ± 0.8	0.001	
 FVC, % predicted	93.8 ± 11.5	93.9 ± 11.3	86.3 ± 14.6	< 0.001	93.6 ± 13.7	86.3 ± 14.6	< 0.001	
 FEV1, L	3.0 ± 0.7	3.0 ± 0.7	2.4 ± 0.6	< 0.001	2.5 ± 0.6	2.4 ± 0.6	< 0.001	
 FEV1, % predicted	99.10 ± 14.3	99.1 ± 14.2	88.2 ± 15.2	< 0.001	98.5 ± 17.3	88.2 ± 15.2	< 0.001	
 FEV1/FVC (%)	81.1 ± 6.3	81.2 ± 6.3	77.2 ± 8.5	< 0.001	79.0 ± 7.1	77.2 ± 8.5	< 0.001	
COPD development	2,272 (2.5)	2,031 (2.3)	241 (14.0)	< 0.001	293 (4.3)	241 (14.0)	< 0.001	
Change in lung function								
 FEV1 decline, mL/year	38.4 ± 132.9	37.7 ± 131.8	77.6 ± 176.0	< 0.001	47.3 ± 126.6	77.6 ± 176.0	< 0.001	
 Rapid FEV1 decline*	34,794 (37.9)	34,017 (37.8)	777 (45.3)	< 0.001	2,598 (37.9)	777 (45.3)	< 0.001	
Data are expressed as mean ± standard deviation or number (%)

*Decline in FEV1 > 60 mL/year is defined as a rapid FEV1 decline

Abbreviations: NTM-PD, nontuberculous mycobacterial pulmonary disease; FVC, forced vital capacity; FEV1, forced expiratory volume in 1 s; COPD, chronic obstructive pulmonary disease

Incidence and risk of COPD

In study 1, during a mean follow-up of 3.3 years, 14.0% of patients in the NTM-PD group (241/1,1715) and 4.3% of patients in the matched control group (293/6,860) developed COPD. In the multivariable-adjusted model, the adjusted HR (aHR) was 2.57 (95% CI: 2.15–3.09) for the comparison of incident COPD between the NTM-PD and matched control groups. In the subgroup analysis, the risk of incident COPD was more evident in women (aHR = 5.44; 95% CI: 4.11–7.23) than in men, and in the age group < 60 years (aHR = 6.94; 95% CI: 4.84−9.94) compared to the other group (Table 3). Kaplan–Meier curves also demonstrated a significant difference in the cumulative incidence rate of COPD between the two groups (log-rank p < 0.001, Fig. 2 and Supplementary Fig. 3A).

Table 3 Association between NTM-PD and COPD development

	n	Incident cases of COPD
(n [%])	Unadjusted HR
(95% CI)	Adjusted HR*
(95% CI)	
Before matching					
 Control cohort	90,088	2,031 (2.3)	Reference	Reference	
 NTM-PD cohort	1,715	241 (14.0)	5.46 (4.78–6.24)	1.81 (1.54–2.13)	
After matching					
 Matched control cohort	6,860	293 (4.3)	Reference	Reference	
 NTM-PD cohort	1,715	241 (14.0)	3.02 (2.54–3.58)	2.57 (2.15–3.09)	
Sex					
 Male					
  Matched control cohort	2,560	209 (8.2)	Reference	Reference	
  NTM-PD cohort	735	120 (16.3)	1.84 (1.47–2.30)	1.56 (1.23–1.97)	
 Female					
  Matched control cohort	4,300	84 (2.0)	Reference	Reference	
  NTM-PD cohort	980	121 (12.3)	5.75 (4.36–7.61)	5.44 (4.11–7.23)	
Age					
 < 60 years					
     Matched control cohort	3,111	48 (1.5)	Reference	Reference	
     NTM-PD cohort	686	80 (11.7)	7.18 (5.02–10.26)	6.94 (4.84–9.94)	
 ≥ 60 years					
     Matched control cohort	3,749	245 (6.5)	Reference	Reference	
     NTM-PD cohort	1,029	161 (15.6)	2.17 (1.78–2.65)	2.01 (1.63–2.47)	
*Adjusted for age, sex, BMI, smoking status, and comorbidities (tuberculosis, hypertension, diabetes mellitus, ischemic heart disease, and cerebrovascular disease)

Abbreviations: NTM-PD, nontuberculous mycobacterial pulmonary disease; COPD, chronic obstructive pulmonary disease; HR, hazard ratio; CI, confidence interval; BMI, body mass index

Fig. 2 Cumulative incidence of COPD according to the presence or absence of NTM-PD in study 1 (NTM-PD cohort versus matched control cohort). Abbreviations: NTM-PD, nontuberculous mycobacterial pulmonary disease; COPD, chronic obstructive pulmonary disease

Validation with NHIS-NSC data (study 2)

Supplementary Table 1 presents the baseline characteristics of the patients with NTM-PD and 1:3 age- and sex-matched controls of study 2. Although the smoking status did not differ significantly, patients with NTM-PD exhibited a lower BMI and higher Charlson comorbidity index than those of the matched controls. Furthermore, 6.2% (24/386) and 2.5% (28/1,133) of the patients with and without NTM-PD, respectively, developed COPD with respective incidence rates of 14.8 and 5.3 per 100,000 person-years (Table 4). The NTM-PD cohort exhibited a higher risk of COPD (aHR = 2.04; 95% CI: 1.21–3.42) than that of the matched control cohort. Similarly, the cumulative incidence rate of COPD differed significantly between the two groups (log-rank p < 0.001, Supplementary Fig. 3B). In the subgroup analysis, the risk of incident COPD was more evident in women (aHR = 3.55; 95% CI: 1.65−7.62) than in men.

Table 4 Overall and sex- and age-specific incidence rates and HR for COPD in the NTM-PD and matched control cohorts using a nationwide cohort dataset

	Cases	Incidence rate
(/100,000 PY)	Sub-distribution hazard ratio (95% CI)	
Unadjusted HR	Adjusted HR*	
Overall					
 Matched control cohort	28	5.3	Reference	Reference	
 NTM-PD cohort	24	14.8	2.10 (1.30–3.38)	2.04 (1.21–3.42)	
Sex					
 Male					
  Matched control cohort	16	8.0	Reference	Reference	
  NTM-PD cohort	6	10.6	1.05 (0.48–2.30)	0.94 (0.41–2.13)	
 Female					
  Matched control cohort	12	3.7	Reference	Reference	
  NTM-PD cohort	18	17.1	3.50 (1.84–6.67)	3.55 (1.65–7.62)	
Age					
 < 60 years					
  Matched control cohort	8	2.8	Reference	Reference	
  NTM-PD cohort	14	15.9	3.71 (1.64–8.37)	1.93 (0.73–5.07)	
 ≥ 60 years					
  Matched control cohort	20	8.1	Reference	Reference	
  NTM-PD cohort	10	13.5	1.49 (0.80–2.75)	1.68 (0.86–3.27)	
*Adjusted for BMI and Charlson comorbidity index

The smoking status was not adjusted for because it did not differ significantly between the two groups

Abbreviations: HR, hazard ratio; COPD, chronic obstructive pulmonary disease; NTM-PD, nontuberculous mycobacterial pulmonary disease; PY, per year; CI, confidence interval

Discussion

The present study provided longitudinal evidence for the association between NTM-PD and the development of COPD, utilizing a single-center database with a large number of patients with NTM-PD. Patients with NTM-PD exhibited a greater decline in lung function and approximately 2.5-fold higher risk of COPD incidence than those of the matched controls without NTM-PD. These findings were validated using a nationally representative cohort with similar hazard magnitudes. Notably, most (74–85%) patients in both cohorts were never-smokers, underscoring the potential role of NTM-PD as a major etiological factor in COPD-I.

Previous studies have reported lung function decline in patients with NTM-PD based on clinical outcomes or disease severity [11–14]. In a previous study where patients with NTM-PD (n = 358) were categorized into treatment-failure (n = 68), observation (n = 118), and treatment-success (n = 172) groups, FEV1 decline was faster in the treatment-failure group compared to other groups (52.2, 30.8, and 28.2 mL/year, respectively) [11]. Even after adjusting for multiple confounders, NTM-PD treatment failure was significantly associated with a greater decline in lung function. Additionally, in the treatment failure group, approximately 16% (5/31) of patients with normal spirometry results at baseline transitioned to obstructive spirometry. A recent study in South Korea categorized patients with NTM-PD (n = 354) into mild, moderate, and severe groups based on the BMI, age, cavity, erythrocyte sedimentation rate, and sex (BACES) severity score system [32] and reported that the annual declines in FEV1, FVC, and diffusing capacity for carbon monoxide increased with increasing disease severity of NTM-PD [13]. FEV1 decreased by 26.4, 31.3, and 35.7 mL/year in mild, moderate, and severe groups, respectively [13]. By demonstrating that treatment failure and severe NTM-PD were associated with a faster FEV1 decline, these studies supported the notion that NTM-PD is a risk factor for COPD development. However, these studies focused on lung function decline among patients with NTM-PD and did not compare them with healthy controls. A comparative study from Japan included 22 never-smokers with NTM-PD and 9 healthy never-smokers. Although the sample size was small, the FEV1 decline was significantly greater in the NTM-PD group than in the control group (− 70 vs. 20 mL/year) [12]. Our present study, which included a large number of patients with NTM-PD and matched controls, confirmed a greater lung function decline in patients with NTM-PD than in those without NTM-PD. Notably, we excluded patients with abnormal lung function or the diagnosis of COPD at baseline.

Regarding the association between NTM-PD and COPD development, a previous study using Taiwanese National Health Insurance data reported that the incidence of COPD was approximately 3.0-fold higher in the NTM cohort than in the non-NTM cohort [4]. However, this study did not include information on the smoking status and BMI. Since smoking exposure is a major risk factor for COPD, the lack of smoking status data was a notable limitation of this study. The present study overcomes these limitations and is the first to report a higher incidence of COPD in patients with NTM-PD than in smoking status-matched controls. An important strength of the present study was its longitudinal cohort design, which utilized a relatively large-scale and comprehensive dataset from a tertiary referral center and validation with a nationwide dataset. In study 1, the NTM-PD diagnosis was objectively defined using ICD-10 codes and microbiological findings. Using spirometry data, we objectively measured COPD development and excluded those with abnormal spirometry results at baseline. In study 2, we demonstrated the association between NTM-PD and COPD treatment, extending beyond spirometry-defined COPD in real-world clinical settings. These findings suggest that, akin to pulmonary tuberculosis, NTM-PD serves as a risk factor for COPD.

Considering the substantial incidence of radiographic airway involvement, including bronchiolitis and parenchymal destruction involving the alveoli [33], an association between NTM-PD and airflow obstruction is predictable. In patients with NTM-PD whose spirometry test is apparently “normal,” a mild obstructive pattern and gas trapping may be present [14]. Although the pathogenesis of NTM-PD has not been fully investigated, recurrent and persistent NTM infections are related to impaired mucociliary clearance and Th1 immune deficiency in the host [34]. Moreover, NTM species can damage the airway cilia, creating a vicious cycle that further impairs mucociliary clearance [35]. NTM infection induces airway inflammation and excessive neutrophilic response, which can compromise the airways, leading to pathological remodeling similar to that in tuberculosis (e.g., bronchiolitis, bronchiectasis, or cavity formation), [36] which is now recognized as a major etiotype of COPD-I. Therefore, persistent NTM infection and NTM-related inflammation may be responsible for COPD development.

This study has several clinical implications. First, it highlights the need for healthcare workers, patients, and local communities to recognize that NTM-PD can be associated with the development of COPD. Considering the increasing global prevalence of NTM-PD, COPD related to this disease might have been on the rise; however, without awareness of this association, its burden is likely to remain under-recognized. We suggest two strategies to ameliorate COPD progression in patients with NTM-PD. The first involves regular measurement of lung function in this population. Although the current guidelines for the NTM-PD diagnosis and treatment focus on identification and eradication of the causative microorganism, they do not mention lung function measurement or COPD development in patients with NTM-PD [7]. Close monitoring of symptoms, radiologic progression, and lung function could aid in the early detection of COPD. The second strategy entails the appropriate treatment of NTM-PD, as inappropriate treatment of NTM-PD is relatively common in real-world settings [37]. Because treatment failure could more rapidly decline lung function, which might lead to the COPD development, emphasizing appropriate NTM-PD treatment is crucial. Second, this study suggests the requirement for more basic research to elucidate the underlying mechanisms of COPD development in patients with NTM-PD. Unveiling specific molecular signaling pathways may help identify early biomarkers predicting COPD development and potential treatment-targeting molecules for this specific phenotype of COPD in patients with NTM-PD.

Despite its strengths, this study had several limitations. First, NTM-PD was diagnosed based on the presence of ICD-10 codes and microbiological findings. Therefore, patients with mild or asymptomatic NTM-PD or undiagnosed NTM-PD, such as cases where NTM species were isolated from only one sputum specimen, might not have been included in this study. Second, the incidence of COPD was higher in study 1 than in study 2. The potential reasons for overestimation in study 1 are as follows: (1) Study 1 was conducted at a tertiary referral hospital with a large number of patients with NTM-PD. The patients with NTM-PD in the present study were likely to experience more severe disease (and were more prone to developing COPD) compared to those with NTM-PD in general. (2) We defined newly diagnosed COPD as the first detected airflow obstruction using pre-bronchodilator spirometry results. Thus, a transient airflow obstruction could have been captured as COPD, and pre-bronchodilator airflow obstruction could have overestimated COPD. (3) Study 2 defined COPD as the ICD-10 codes for COPD and use of bronchodilators [20, 21, 38]. Since patients with ICD-10 codes for COPD who were not under treatment were not considered as having COPD, this could also lead to the discrepancy in the prevalence of COPD between the studies [39]. Fourth, as this study utilized data extracted from the CDW and NHIS-NSC, we lacked information on the presence and extent of coexisting bronchiectasis, pulmonary fibrosis, clinical phenotype of NTM-PD (nodular bronchiectasis or fibrocavitary), and severity of NTM-PD. In evaluating the association between NTM-PD and COPD risk, we were unable to consider some important variables, such as bronchiectasis and pulmonary fibrosis [40, 41] due to the following reasons: Our study relied on formal interpretations of chest CT findings by radiologists, who sometimes omit detailed descriptions of bronchiectasis and/or fibrosis when interpreting CT findings of patients with NTM-PD. Consequently, the presence of bronchiectasis and/or fibrosis may be underreported. Additionally, clinicians often record the ICD-10 code for NTM-PD while omitting codes for bronchiectasis or fibrosis. Given these constraints, bronchiectasis and pulmonary fibrosis were not included in our study. Further studies with more detailed information are required to explore the association between NTM-PD and COPD. Fifth, our study spans a considerable period during which both the prevalence and awareness of NTM-PD have increased substantially. This could have influenced the timing of diagnosis and initiation of antibiotic treatment for NTM-PD, potentially affecting the observed association between NTM-PD and the development of COPD. Future studies are warranted to address these remaining questions. Finally, as this study was conducted in South Korea, the generalizability of the results to other ethnic groups or countries may be limited.

Conclusion

In conclusion, patients with NTM-PD experienced a greater decline in lung function and a significantly higher incidence rate of COPD compared to those without NTM-PD. These findings emphasize the importance of monitoring lung function in patients with NTM-PD to improve their clinical prognosis.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary Material 1: Supplementary Text. Supplementary Methods, Supplementary Figure Legends, Supplementary Table 1

Supplementary Material 2: Supplementary Figure 1. Flowchart of the study population using the nationwide dataset. Abbreviations: NTM-PD, nontuberculous mycobacterial pulmonary disease; COPD, chronic obstructive pulmonary disease

Supplementary Material 3: Supplementary Figure 2. Graph illustrating the change in standardized mean difference. Abbreviations: BMI, body mass index

Supplementary Material 4: Supplementary Figure 3. (A) Cumulative incidence of COPD according to the presence of NTM-PD in study 1 (NTM-PD cohort versus whole control). Abbreviations: NTM-PD, nontuberculous mycobacterial pulmonary disease; COPD, chronic obstructive pulmonary disease

Supplementary Material 5: Supplementary Figure 3. (B) Cumulative incidence of COPD (/100,000 person-years) in the NTM-PD and matched cohorts using the nationwide dataset. Abbreviations: NTM-PD, nontuberculous mycobacterial pulmonary disease; COPD, chronic obstructive pulmonary disease

Acknowledgements

We express our heartfelt gratitude and respect to Won-Jung Koh for constructing the comprehensive patient dataset for study 1. Won-Jung Koh passed away in August 2019. We dedicate this work to his memory.

Author contributions

H.L. is the guarantors of the manuscript and take responsibility for its content, including the data and analysis. B.-G.K., S.H.S. and H.L. contributed to the conception and design of the study. B.-G.K., S.H.S., S.-K., L. and H.L. were involved in the collection and interpretation of the data. B.-G.K. and S.-K.L. were involved in the statistical analyses. B.-G.K. and S.H.S. were a major contributor in writing the manuscript. All authors have read and approved the final manuscript.

Funding

None.

Data availability

No datasets were generated or analysed during the current study.

Declarations

Ethics approval and consent to participate

Study 1 was approved by the Institutional Review Board of the Samsung Medical Center (IRB no.: SMC 2023-08-084). Study 2 was approved by the Institutional Review Board of the Hanyang University Hospital (IRB no.: HYUH 2023-06-007). The requirement for obtaining informed consent was waived because the CDW and NHIS databases were constructed after anonymization. These studies were conducted in accordance with the principles of the Declaration of Helsinki.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Bo-Guen Kim and Sun Hye Shin contributed equally to this work.
==== Refs
References

1. Prevalence and attributable health burden of chronic respiratory diseases 1990–2017: a systematic analysis for the global burden of Disease Study 2017 Lancet Respir Med 2020 8 585 96 10.1016/S2213-2600(20)30105-3 32526187
Prevalence and attributable health burden of chronic respiratory diseases. 1990–2017: a systematic analysis for the global burden of Disease Study 2017. Lancet Respir Med. 2020;8:585–96.32526187 10.1016/S2213-2600(20)30105-3
2. World Health Organization. 2019. Leading Causes of Death Globally. https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death
3. The Global Strategy for Diagnosis. Management and Prevention of COPD (updated 2023), http://www.goldcopd.org. [Accessed Feb 7 2023].
4. Yeh JJ Wang YC Sung FC Chou CY Kao CH Nontuberculosis mycobacterium disease is a risk factor for chronic obstructive pulmonary disease: a nationwide cohort study Lung 2014 192 403 11 10.1007/s00408-014-9574-9 24691889
Yeh JJ, Wang YC, Sung FC, Chou CY, Kao CH. Nontuberculosis mycobacterium disease is a risk factor for chronic obstructive pulmonary disease: a nationwide cohort study. Lung. 2014;192:403–11.24691889 10.1007/s00408-014-9574-9
5. Lee MK Kim SB Shin B Differences in the clinical characteristics of chronic pulmonary aspergillosis according to spirometric impairment PLoS ONE 2021 16 e0260274 10.1371/journal.pone.0260274 34807947
Lee MK, Kim SB, Shin B. Differences in the clinical characteristics of chronic pulmonary aspergillosis according to spirometric impairment. PLoS ONE. 2021;16:e0260274.34807947 10.1371/journal.pone.0260274
6. Alvar A Antonio A Bartolome RC Kevin M Sundeep S Claus FV GOLD 2023 executive Summary: responses from the GOLD Scientific Committee Eur Respir J 2023 61 2300616 10.1183/13993003.00616-2023 37321613
Alvar A, Antonio A, Bartolome RC, Kevin M, Sundeep S, Claus FV. GOLD 2023 executive Summary: responses from the GOLD Scientific Committee. Eur Respir J. 2023;61:2300616.37321613 10.1183/13993003.00616-2023
7. Lee H, Shin SH, Park HY, Lim SY. Can we call all obstructive lung diseases COPD? Eur Respir J 2023; 61(6).
8. Daley CL Iaccarino JM Lange C Cambau E Wallace RJ Jr Andrejak C Böttger EC Brozek J Griffith DE Guglielmetti L Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline Eur Respir J 2020 56 2000535 10.1183/13993003.00535-2020 32636299
Daley CL, Iaccarino JM, Lange C, Cambau E, Wallace RJ Jr., Andrejak C, Böttger EC, Brozek J, Griffith DE, Guglielmetti L, et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. Eur Respir J. 2020;56:2000535.32636299 10.1183/13993003.00535-2020
9. Lee SW Park Y Kim S Chung EK Kang YA Comorbidities of nontuberculous mycobacteria infection in Korean adults: results from the National Health Insurance Service-National Sample Cohort (NHIS-NSC) database BMC Pulm Med 2022 22 283 10.1186/s12890-022-02075-y 35870927
Lee SW, Park Y, Kim S, Chung EK, Kang YA. Comorbidities of nontuberculous mycobacteria infection in Korean adults: results from the National Health Insurance Service-National Sample Cohort (NHIS-NSC) database. BMC Pulm Med. 2022;22:283.35870927 10.1186/s12890-022-02075-y
10. Loebinger MR, Quint JK, van der Laan R, Obradovic M, Chawla R, Kishore A, van Ingen J. Risk Factors for Nontuberculous Mycobacterial Pulmonary Disease: A Systematic Literature Review and Meta-Analysis. Chest 2023.
11. Lee MR Yang CY Chang KP Keng LT Yen DH Wang JY Wu HD Lee LN Yu CJ Factors associated with lung function decline in patients with non-tuberculous mycobacterial pulmonary disease PLoS ONE 2013 8 e58214 10.1371/journal.pone.0058214 23483998
Lee MR, Yang CY, Chang KP, Keng LT, Yen DH, Wang JY, Wu HD, Lee LN, Yu CJ. Factors associated with lung function decline in patients with non-tuberculous mycobacterial pulmonary disease. PLoS ONE. 2013;8:e58214.23483998 10.1371/journal.pone.0058214
12. Park HY Jeong BH Chon HR Jeon K Daley CL Koh WJ Lung function decline according to clinical course in Nontuberculous Mycobacterial Lung Disease Chest 2016 150 1222 32 10.1016/j.chest.2016.06.005 27298072
Park HY, Jeong BH, Chon HR, Jeon K, Daley CL, Koh WJ. Lung function decline according to clinical course in Nontuberculous Mycobacterial Lung Disease. Chest. 2016;150:1222–32.27298072 10.1016/j.chest.2016.06.005
13. Kobayashi T Tsuyuguchi K Arai T Tsuji T Maekura T Kurahara Y Sugimoto C Minomo S Nakao K Tokura S Change in lung function in never-smokers with nontuberculous mycobacterial lung disease: a retrospective study J Clin Tuberc Other Mycobact Dis 2018 11 17 21 10.1016/j.jctube.2018.02.002 31720386
Kobayashi T, Tsuyuguchi K, Arai T, Tsuji T, Maekura T, Kurahara Y, Sugimoto C, Minomo S, Nakao K, Tokura S, et al. Change in lung function in never-smokers with nontuberculous mycobacterial lung disease: a retrospective study. J Clin Tuberc Other Mycobact Dis. 2018;11:17–21.31720386 10.1016/j.jctube.2018.02.002
14. Park HJ Kim JY Kim HJ Yim JJ Kwak N Lung function decline in non-tuberculous mycobacterial pulmonary disease according to disease severity Int J Tuberc Lung Dis 2023 27 465 70 10.5588/ijtld.22.0616 37231609
Park HJ, Kim JY, Kim HJ, Yim JJ, Kwak N. Lung function decline in non-tuberculous mycobacterial pulmonary disease according to disease severity. Int J Tuberc Lung Dis. 2023;27:465–70.37231609 10.5588/ijtld.22.0616
15. Mehta M Chapman KR Heffer M Marras TK Impact of pulmonary nontuberculous mycobacterial treatment on pulmonary function tests in patients with and without established obstructive lung disease Respirology 2015 20 987 93 10.1111/resp.12565 26011313
Mehta M, Chapman KR, Heffer M, Marras TK. Impact of pulmonary nontuberculous mycobacterial treatment on pulmonary function tests in patients with and without established obstructive lung disease. Respirology. 2015;20:987–93.26011313 10.1111/resp.12565
16. Huang CT Tsai YJ Wu HD Wang JY Yu CJ Lee LN Yang PC Impact of non-tuberculous mycobacteria on pulmonary function decline in chronic obstructive pulmonary disease Int J Tuberc Lung Dis 2012 16 539 45 10.5588/ijtld.11.0412 22325332
Huang CT, Tsai YJ, Wu HD, Wang JY, Yu CJ, Lee LN, Yang PC. Impact of non-tuberculous mycobacteria on pulmonary function decline in chronic obstructive pulmonary disease. Int J Tuberc Lung Dis. 2012;16:539–45.22325332 10.5588/ijtld.11.0412
17. Kim SH Jhun BW Jeong BH Park HY Kim H Kwon OJ Shin SH The higher incidence of COVID-19 in patients with Non-tuberculous Mycobacterial Pulmonary Disease: a single Center experience in Korea J Korean Med Sci 2022 37 e250 10.3346/jkms.2022.37.e250 35971764
Kim SH, Jhun BW, Jeong BH, Park HY, Kim H, Kwon OJ, Shin SH. The higher incidence of COVID-19 in patients with Non-tuberculous Mycobacterial Pulmonary Disease: a single Center experience in Korea. J Korean Med Sci. 2022;37:e250.35971764 10.3346/jkms.2022.37.e250
18. Shin DW Cho B Guallar E Korean National Health Insurance Database JAMA Intern Med 2016 176 138 10.1001/jamainternmed.2015.7110 26747667
Shin DW, Cho B, Guallar E. Korean National Health Insurance Database. JAMA Intern Med. 2016;176:138.26747667 10.1001/jamainternmed.2015.7110
19. Lee H Park HJ Cho SN Bai GH Kim SJ Species identification of mycobacteria by PCR-restriction fragment length polymorphism of the rpoB gene J Clin Microbiol 2000 38 2966 71 10.1128/JCM.38.8.2966-2971.2000 10921960
Lee H, Park HJ, Cho SN, Bai GH, Kim SJ. Species identification of mycobacteria by PCR-restriction fragment length polymorphism of the rpoB gene. J Clin Microbiol. 2000;38:2966–71.10921960 10.1128/JCM.38.8.2966-2971.2000
20. Park HY Kang D Shin SH Yoo KH Rhee CK Suh GY Kim H Shim YM Guallar E Cho J Kwon OJ Chronic obstructive pulmonary disease and lung cancer incidence in never smokers: a cohort study Thorax 2020 75 506 9 10.1136/thoraxjnl-2019-213732 32241883
Park HY, Kang D, Shin SH, Yoo KH, Rhee CK, Suh GY, Kim H, Shim YM, Guallar E, Cho J, Kwon OJ. Chronic obstructive pulmonary disease and lung cancer incidence in never smokers: a cohort study. Thorax. 2020;75:506–9.32241883 10.1136/thoraxjnl-2019-213732
21. Park HY Kang D Shin SH Choi H Jang SH Lee CH Kim H Kwon OJ Rhee CK Cho J Pulmonary tuberculosis and the incidence of Lung Cancer among patients with chronic obstructive Pulmonary Disease Ann Am Thorac Soc 2022 19 640 8 10.1513/AnnalsATS.202010-1240OC 34478360
Park HY, Kang D, Shin SH, Choi H, Jang SH, Lee CH, Kim H, Kwon OJ, Rhee CK, Cho J. Pulmonary tuberculosis and the incidence of Lung Cancer among patients with chronic obstructive Pulmonary Disease. Ann Am Thorac Soc. 2022;19:640–8.34478360 10.1513/AnnalsATS.202010-1240OC
22. Miller M ATS/ERS task force: standardisation of spirometry Eur Respir J 2005 26 319 38 10.1183/09031936.05.00034805 16055882
Miller M. ATS/ERS task force: standardisation of spirometry. Eur Respir J. 2005;26:319–38.16055882 10.1183/09031936.05.00034805
23. Choi JK Paek D Lee JO Normal predictive values of Spirometry in Korean Population Tuberc Respir Dis 2005 58 230 42 10.4046/trd.2005.58.3.230
Choi JK, Paek D, Lee JO. Normal predictive values of Spirometry in Korean Population. Tuberc Respir Dis. 2005;58:230–42.10.4046/trd.2005.58.3.230
24. Lange P Celli B Agustí A Boje Jensen G Divo M Faner R Guerra S Marott JL Martinez FD Martinez-Camblor P Lung-function trajectories leading to Chronic Obstructive Pulmonary Disease N Engl J Med 2015 373 111 22 10.1056/NEJMoa1411532 26154786
Lange P, Celli B, Agustí A, Boje Jensen G, Divo M, Faner R, Guerra S, Marott JL, Martinez FD, Martinez-Camblor P, et al. Lung-function trajectories leading to Chronic Obstructive Pulmonary Disease. N Engl J Med. 2015;373:111–22.26154786 10.1056/NEJMoa1411532
25. Martinez FJ Han MK Allinson JP Barr RG Boucher RC Calverley PMA Celli BR Christenson SA Crystal RG Fagerås M At the Root: defining and halting progression of early chronic obstructive Pulmonary Disease Am J Respir Crit Care Med 2018 197 1540 51 10.1164/rccm.201710-2028PP 29406779
Martinez FJ, Han MK, Allinson JP, Barr RG, Boucher RC, Calverley PMA, Celli BR, Christenson SA, Crystal RG, Fagerås M, et al. At the Root: defining and halting progression of early chronic obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2018;197:1540–51.29406779 10.1164/rccm.201710-2028PP
26. Choi H Lee H Lee SK Yang B Chung SJ Yeo Y Park TS Park DW Moon JY Kim TH Impact of bronchiectasis on susceptibility to and severity of COVID-19: a nationwide cohort study Ther Adv Respir Dis 2021 15 1753466621995043 10.1177/1753466621995043 33583345
Choi H, Lee H, Lee SK, Yang B, Chung SJ, Yeo Y, Park TS, Park DW, Moon JY, Kim TH, et al. Impact of bronchiectasis on susceptibility to and severity of COVID-19: a nationwide cohort study. Ther Adv Respir Dis. 2021;15:1753466621995043.33583345 10.1177/1753466621995043
27. Choi H Yang B Kim YJ Sin S Jo YS Kim Y Park HY Ra SW Oh YM Chung SJ Increased mortality in patients with non cystic fibrosis bronchiectasis with respiratory comorbidities Sci Rep 2021 11 7126 10.1038/s41598-021-86407-8 33782457
Choi H, Yang B, Kim YJ, Sin S, Jo YS, Kim Y, Park HY, Ra SW, Oh YM, Chung SJ, et al. Increased mortality in patients with non cystic fibrosis bronchiectasis with respiratory comorbidities. Sci Rep. 2021;11:7126.33782457 10.1038/s41598-021-86407-8
28. Lee H, Choi H, Yang B, Lee SK, Park TS, Park DW, Moon JY, Kim TH, Sohn JW, Yoon HJ, Kim SH. Interstitial lung disease increases susceptibility to and severity of COVID-19. Eur Respir J 2021, 58.
29. Yang B Ryu J Kim T Jo YS Kim Y Park HY Kang YA Lee SJ Lee OJ Moon JY Impact of Bronchiectasis on Incident Nontuberculous Mycobacterial Pulmonary Disease: a 10-Year National Cohort Study Chest 2021 159 1807 11 10.1016/j.chest.2020.12.020 33373596
Yang B, Ryu J, Kim T, Jo YS, Kim Y, Park HY, Kang YA, Lee SJ, Lee OJ, Moon JY, et al. Impact of Bronchiectasis on Incident Nontuberculous Mycobacterial Pulmonary Disease: a 10-Year National Cohort Study. Chest. 2021;159:1807–11.33373596 10.1016/j.chest.2020.12.020
30. Yoo JE Kim D Han K Rhee SY Shin DW Lee H Diabetes Status and Association with risk of tuberculosis among Korean adults JAMA Netw Open 2021 4 e2126099 10.1001/jamanetworkopen.2021.26099 34546370
Yoo JE, Kim D, Han K, Rhee SY, Shin DW, Lee H. Diabetes Status and Association with risk of tuberculosis among Korean adults. JAMA Netw Open. 2021;4:e2126099.34546370 10.1001/jamanetworkopen.2021.26099
31. Zhang Z Kim HJ Lonjon G Zhu Y Balance diagnostics after propensity score matching Ann Transl Med 2019 7 16 10.21037/atm.2018.12.10 30788363
Zhang Z, Kim HJ, Lonjon G, Zhu Y. Balance diagnostics after propensity score matching. Ann Transl Med. 2019;7:16.30788363 10.21037/atm.2018.12.10
32. Kim HJ Kwak N Hong H Kang N Im Y Jhun BW Yim JJ BACES score for Predicting Mortality in Nontuberculous Mycobacterial Pulmonary Disease Am J Respir Crit Care Med 2021 203 230 6 10.1164/rccm.202004-1418OC 32721164
Kim HJ, Kwak N, Hong H, Kang N, Im Y, Jhun BW, Yim JJ. BACES score for Predicting Mortality in Nontuberculous Mycobacterial Pulmonary Disease. Am J Respir Crit Care Med. 2021;203:230–6.32721164 10.1164/rccm.202004-1418OC
33. Fujita J Ohtsuki Y Suemitsu I Shigeto E Yamadori I Obayashi Y Miyawaki H Dobashi N Matsushima T Takahara J Pathological and radiological changes in resected lung specimens in Mycobacterium avium intracellulare complex disease Eur Respir J 1999 13 535 40 10.1183/09031936.99.13353599 10232422
Fujita J, Ohtsuki Y, Suemitsu I, Shigeto E, Yamadori I, Obayashi Y, Miyawaki H, Dobashi N, Matsushima T, Takahara J. Pathological and radiological changes in resected lung specimens in Mycobacterium avium intracellulare complex disease. Eur Respir J. 1999;13:535–40.10232422 10.1183/09031936.99.13353599
34. Matsuyama M Ishii Y Yageta Y Ohtsuka S Ano S Matsuno Y Morishima Y Yoh K Takahashi S Ogawa K Role of Th1/Th17 balance regulated by T-bet in a mouse model of Mycobacterium avium complex disease J Immunol 2014 192 1707 17 10.4049/jimmunol.1302258 24446514
Matsuyama M, Ishii Y, Yageta Y, Ohtsuka S, Ano S, Matsuno Y, Morishima Y, Yoh K, Takahashi S, Ogawa K, et al. Role of Th1/Th17 balance regulated by T-bet in a mouse model of Mycobacterium avium complex disease. J Immunol. 2014;192:1707–17.24446514 10.4049/jimmunol.1302258
35. Middleton AM Chadwick MV Nicholson AG Dewar A Groger RK Brown EJ Wilson R The role of Mycobacterium avium complex fibronectin attachment protein in adherence to the human respiratory mucosa Mol Microbiol 2000 38 381 91 10.1046/j.1365-2958.2000.02137.x 11069663
Middleton AM, Chadwick MV, Nicholson AG, Dewar A, Groger RK, Brown EJ, Wilson R. The role of Mycobacterium avium complex fibronectin attachment protein in adherence to the human respiratory mucosa. Mol Microbiol. 2000;38:381–91.11069663 10.1046/j.1365-2958.2000.02137.x
36. Matsuyama M Matsumura S Nonaka M Nakajima M Sakai C Arai N Ueda K Hizawa N Pathophysiology of pulmonary nontuberculous mycobacterial (NTM) disease Respir Investig 2023 61 135 48 10.1016/j.resinv.2022.12.002 36640546
Matsuyama M, Matsumura S, Nonaka M, Nakajima M, Sakai C, Arai N, Ueda K, Hizawa N. Pathophysiology of pulmonary nontuberculous mycobacterial (NTM) disease. Respir Investig. 2023;61:135–48.36640546 10.1016/j.resinv.2022.12.002
37. van Jakko I Dirk W Jack G Kozo M Christoph L Charles SH Floto RA Jennifer A Prevots DR David EG: poor adherence to management guidelines in nontuberculous mycobacterial pulmonary diseases Eur Respir J 2017 49 1601855 10.1183/13993003.01855-2016 28182571
van Jakko I, Dirk W, Jack G, Kozo M, Christoph L, Charles SH, Floto RA, Jennifer A, Prevots DR. David EG: poor adherence to management guidelines in nontuberculous mycobacterial pulmonary diseases. Eur Respir J. 2017;49:1601855.28182571 10.1183/13993003.01855-2016
38. Kim BG Lee H Kang MG Kim JS Moon JY Risk of Ischemic Heart Disease in Chronic Obstructive Pulmonary Disease: a Nationwide Cohort Study J Korean Med Sci 2023 38 e344 10.3346/jkms.2023.38.e344 37904657
Kim BG, Lee H, Kang MG, Kim JS, Moon JY. Risk of Ischemic Heart Disease in Chronic Obstructive Pulmonary Disease: a Nationwide Cohort Study. J Korean Med Sci. 2023;38:e344.37904657 10.3346/jkms.2023.38.e344
39. Kim T Choi H Kim SH Yang B Han K Jung JH Kim BG Park DW Moon JY Kim SH Increased risk of Incident Chronic Obstructive Pulmonary Disease and related hospitalizations in tuberculosis survivors: a Population-based Matched Cohort Study J Korean Med Sci 2024 39 e105 10.3346/jkms.2024.39.e105 38529575
Kim T, Choi H, Kim SH, Yang B, Han K, Jung JH, Kim BG, Park DW, Moon JY, Kim SH, et al. Increased risk of Incident Chronic Obstructive Pulmonary Disease and related hospitalizations in tuberculosis survivors: a Population-based Matched Cohort Study. J Korean Med Sci. 2024;39:e105.38529575 10.3346/jkms.2024.39.e105
40. Faverio P, Stainer A, Bonaiti G, Zucchetti SC, Simonetta E, Lapadula G, Marruchella A, Gori A, Blasi F, Codecasa L et al. Characterizing non-tuberculous mycobacteria infection in Bronchiectasis. Int J Mol Sci 2016, 17.
41. Odashima K Kagiyama N Kanauchi T Ishiguro T Takayanagi N Incidence and etiology of chronic pulmonary infections in patients with idiopathic pulmonary fibrosis PLoS ONE 2020 15 e0230746 10.1371/journal.pone.0230746 32243456
Odashima K, Kagiyama N, Kanauchi T, Ishiguro T, Takayanagi N. Incidence and etiology of chronic pulmonary infections in patients with idiopathic pulmonary fibrosis. PLoS ONE. 2020;15:e0230746.32243456 10.1371/journal.pone.0230746
